Bristol-Myers Squibb Co (BMY) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Bristol-Myers Squibb Co (BMY) scores 6.3 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on profitability, and growth is what holds it back.
One pillar, solvency, is unscored because the filings behind it carry too little to judge. It is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Bristol-Myers Squibb Co yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
Bristol-Myers Squibb Co (BMY) has a Lemma Quality Score of 6.3 out of 10 as of October 19, 2026, which reads as solid quality. A solid reading is a respectable business with clear strengths and at least one area that falls short of the best in its field. Five pillars feed it, and every one of them is computed from what the company reported rather than from its share price.
Set against 212 Healthcare companies, Bristol-Myers Squibb Co lands at the 80th percentile, among the stronger quarter of the group. The median across the group is 4.4, and the top quarter begins at 6.0, so Bristol-Myers Squibb Co is well above the typical company here.
Bristol-Myers Squibb Co’s profitability score is 8.6 out of 10 (strong). Against a median of 2.7 among 210 Healthcare companies, that is well above the group and the 94th percentile. Returns and margins at this level leave room to reinvest, absorb a bad year or return cash to shareholders without straining the business.
There is no solvency score for Bristol-Myers Squibb Co: too little of the pillar could be measured from the filings to give an honest reading. The overall is therefore the weighted average of the other pillars. Across 150 Healthcare companies the median for this pillar is 6.5. Without it the overall says nothing about how comfortably the company carries its debt.
On growth, Bristol-Myers Squibb Co scores 3.1, a weak reading. Its peers have a median of 4.9 across 107 Healthcare companies, which places it well below them, at the 31st percentile. When growth is this low the question is whether it is a pause or a trend, and the history behind the filings is the place to look.
On efficiency, Bristol-Myers Squibb Co scores 7.5, a strong reading. Its peers have a median of 6.0 across 200 Healthcare companies, which places it well above them, at the 71st percentile. Efficiency at this level means the company needs comparatively little capital to produce what it sells.
Bristol-Myers Squibb Co’s predictability score is 5.8 out of 10 (average). Against a median of 3.4 among 207 Healthcare companies, that is well above the group and the 79th percentile. Consistency near the median is typical, and it is worth checking whether the swings came from the business itself or from one-off items.
This is a lopsided profile. Profitability scores 8.6 but growth only 3.1, a gap of 5.5 points, so the overall hides a business that is excellent in one respect and weak in another. Leading with profitability is the most valuable kind of strength, because margins and returns are what the other pillars ultimately feed. A growth shortfall often comes with size or a maturing market, and is less of a concern if the other pillars are strong.
The pillar with the most room to move the score is growth. If it rose to the median of Healthcare companies, 4.9, Bristol-Myers Squibb Co’s overall score would go from 6.3 to about 6.8. Only four of the five pillars could be scored. Together they carry 80 of the 100 weight points (the full set is profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and the overall is the weighted average of those alone.
These are the Healthcare companies closest to Bristol-Myers Squibb Co in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Bristol-Myers Squibb Co scores 6.3 out of 10, which reads as solid quality. Its strongest pillar is profitability, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Bristol-Myers Squibb Co ranks at the 80th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Bristol-Myers Squibb Co’s 6.3.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for BMY are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card